Terilyn Monroe compensation by year
Guardant Health Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $439,616 |
| Bonus | $0 |
| Stock awards | $2,858,431 |
| Option awards | $1,873,441 |
| Non-equity incentive | $337,500 |
| Pension and deferred compensation | $0 |
| All other | $10,425 |
| Total | $5,519,413 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Guardant Health, Inc. DEF 14A filed April 29, 2025, accession 0001193125-25-103890, and prior-year filings.
How this page was built: the Guardant Health, Inc. filed document, accession 0001193125-25-103890. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 52,136 | $1,592,755 | — |
| PSU | 44,688 | $1,365,218 | — |
| RSU | 31,751 | $969,993 | — |
| PSU | 22,344 | $682,609 | — |
| Option | 78,204 | — | $20.14 |
| Option | 47,627 | — | $28.61 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Guardant Health, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
59 Form 4 lines since the FY2024 proxy (filed April 29, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-18 | Sale | 10b5-1 | 100 | $144.58 | 21,058 |
| 2026-11-18 | Sale | 10b5-1 | 500 | $140.64 | 24,400 |
| 2026-11-18 | Sale | 10b5-1 | 1,338 | $142.83 | 21,862 |
| 2026-11-18 | Sale | 10b5-1 | 704 | $143.64 | 21,158 |
| 2026-11-18 | Sale | 10b5-1 | 1,200 | $141.79 | 23,200 |
| 2026-10-01 | Exercise or conversion derivative | — | 1,360 | $0.00 | 8,162 |
| 2026-10-01 | Exercise or conversion | — | 2,659 | $0.00 | 25,638 |
| 2026-10-01 | Exercise or conversion | — | 1,360 | $0.00 | 26,998 |
The 8 most recent of 59 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments Guardant Health discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $675,000 | $0 | $33,784 | $708,784 |
| Change in control and involuntary termination | $900,000 | $5,517,075 | $50,676 | $6,467,752 |
| Death | $0 | $0 | $0 | $0 |
| Change in control, no termination | $0 | $0 | $0 | $0 |
| Disability | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in Guardant Health, Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
Guardant Health’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| AmirAli Talasaz | Co-Chief Executive Officer | $11,613,545 |
| Helmy Eltoukhy | Chairman and Co-Chief Executive Officer | $11,613,450 |
| Terilyn Monroe · this page | Chief People Officer | $5,519,413 |
| Michael Bell | Chief Financial Officer | $3,606,871 |
| Darya Chudova | Chief Technology Officer | $3,475,523 |
| John Saia | Chief Legal Officer | $3,203,146 |
| Craig Eagle | Chief Medical Officer | $3,111,407 |
The full Guardant Health compensation record
free company briefThis page is one person within Guardant Health's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Guardant Health proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Guardant Health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.